Reading the tape
NASDAQ: PCVX
Vaxcyte, Inc.
Healthcare · Biotechnology
Market Cap
$7.93B
52w High
$65.00
52w Low
$28.09
P/E
-9.75
Volume
123.59K
Outstanding Shares
144.39M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 63.04%FCF (TTM): -15.76%
What changed
The stock rose 63.04% over the last year. Free cash flow declined 15.76% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
CEOGrant E. Pickering
SectorHealthcare
IndustryBiotechnology
Employees414
IPO dateJun 12, 2020
Valuation
Forward P/E—
EV/EBITDA-8.54
Enterprise value$6.33B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-28.55%▼103.42%vs FY2024
Analyst consensus
RatingBuy
Target price$83.00▲51.17%
11
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$1.74 · Revenue est $12.5M
View